The Pennsylvania Department of Drug and Alcohol Programs (DDAP) has launched a new treatment locator called ATLAS (Addiction Treatment Locator, Assessment, and Standards Platform). The platform currently includes 67 percent of licensed treatment facilities in Pennsylvania. DDAP Secretary Jen Smith announced the launch and the benefits of ATLAS in a letter to stakeholders.
The Pennsylvania Insurance Department (PID) is studying the availability of providers in various specialties, including behavioral health, and geographic areas. This is an opportunity for behavioral health providers, including drug and alcohol and mental health providers, to share their challenges in finding and employing specialists required by state regulations and payer contracts and the subsequent access issues that result.
The goal of the study is to understand areas of need based on the current availability of providers to accept new patients, the amount of time it takes to get an appointment with these providers, and the network adequacy considerations based on the findings. PID is seeking public comment from organizations, consumer advocates, providers, and consumers about their experience with getting an appointment or finding available specialists.
On behalf of its behavioral health provider members, RCPA is compiling comments to submit to PID, although members who prefer to submit their comments and experience on their own are encouraged to do so. Providers wanting to submit comments as part of an RCPA response can send them to Drug and Alcohol Division Director Jason Snyder. PID will accept comments until Friday, August 5, so please submit your comments to RCPA by Friday, July 29.
More information can be found in PID’s published Notice for Public Comment.
The Pennsylvania Senate today passed HB 1563 and HB 1561, sending the substance use disorder and mental health confidentiality-related bills to Gov. Wolf to sign into law. He is expected to sign both.
Both bills align Pennsylvania’s confidentiality laws with federal confidentiality laws, including 42 CFR and HIPAA. Barring a Gov. Wolf veto of HB 1563, Pennsylvania’s 4 Pa Code 255.5 will be eliminated.
Advocates of improved care coordination and integration have long pointed to 4 Pa Code 255.5 as a barrier, citing the limited amount of information allowed to be shared and the few entities with whom it could be shared, even with patient consent.
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) today announced the availability of $3 million in funding for entities to provide pregnancy support services to address the needs of pregnant and postpartum women with substance use disorder (SUD).
Eligible applicants can find the project summary and budget on the Funding Opportunities page of the DDAP website. Approximately three to five grants, up to $600,000 each, will be awarded to help provide services, streamline care, and assure that this population is connected with the most appropriate resources to reach long-term recovery.
All applications must be submitted via email by 11:59 pm on Friday, July 29, 2022. Applications will be competitively reviewed and scored based upon the applicant’s adherence to the funding announcement guidelines and a timely submission to DDAP.
The grants are part of $59 million in federal funding awarded to Pennsylvania through the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Substance Abuse Prevention and Treatment Block Grant Program.
Questions regarding the grants and the application process can be emailed to DDAP.
The Substance Abuse and Mental Health Services Administration (SAMHSA) announced today it is extending its opioid treatment program (OTP) exemption for an in-person physical evaluation for buprenorphine treatment for a period of one year from the end of the COVID-19 Public Health Emergency (PHE). The extension goes into effect upon the expiration of the COVID-19 PHE.
Today, the Department of Drug and Alcohol Programs (DDAP) was joined by national nonprofit Shatterproof and substance use disorder treatment provider Gaudenzia to announce the expansion of the free and confidential Addiction Treatment Locator, Assessment, and Standards Platform (ATLAS) to Pennsylvania.
ATLAS evaluates addiction treatment facilities’ use of evidence-based best practices based on the Shatterproof National Principles of Care, includes an assessment to understand the appropriate level of care, and offers an easy-to-use dashboard to allow those in need and their loved ones to search for and compare facilities using criteria such as location, services offered, and insurance accepted so they can find the best treatment for their unique needs. ATLAS is fully available in English and Spanish.
“We are grateful for ATLAS and the team at Shatterproof for making the submission process so easy,” said Dr. Dale Klatzker, President and CEO at Gaudenzia, Inc. “It is vital that we reduce barriers to treatment, and this tool provides an easy way for those in need to seek and quickly find a treatment option that will work best for them.”
Forty Gaudenzia treatment locations and a total of 515 substance use disorder treatment facilities across the state have submitted their information to be included in ATLAS. An additional open enrollment period for facilities who missed the first deadline will be available in fall 2022.
Prev